Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTRB1 | P17538 | 2/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | CASP1 | P29466 | 4/20 | 0.49 |
| ▸ | SYK | P43405 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.46 |
| ▸ | CTSK | P43235 | 2/20 | 0.45 |
| ▸ | TACR1 | P25103 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22296765 | 0.93 | CTRB1 (0.50) | CTRB1HTTLMNASMN1; SMN2CASP1 | |
| SCHEMBL5050621 | 0.86 | HTT (0.57) | HTTLMNASMN1; SMN2FOLH1 | |
| SCHEMBL24725034 | 0.85 | ALDH1A1 (0.44) | CTRB1HTTLMNASMN1; SMN2CASP1 | |
| SCHEMBL31064942 | 0.84 | SYK (0.71) | CTRB1HTTLMNASMN1; SMN2SYK | |
| SCHEMBL24383269 | 0.84 | SYK (0.58) | CTRB1LMNASMN1; SMN2CASP1SYK | |
| SCHEMBL30980753 | 0.84 | CTRB1 (0.54) | CTRB1HTTLMNASMN1; SMN2CASP1 | |
| SCHEMBL30980617 | 0.83 | CTRB1 (0.53) | CTRB1LMNASMN1; SMN2CTSKTACR1 | |
| SCHEMBL25346671 | 0.82 | CTRB1 (0.47) | CTRB1LMNASMN1; SMN2CASP1SYK | |
| SCHEMBL25976345 | 0.82 | CTRB1 (0.47) | CTRB1HTTLMNASMN1; SMN2CASP1 | |
| SCHEMBL31064958 | 0.82 | SYK (0.65) | CTRB1HTTLMNASMN1; SMN2SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250223280-A1 | POTENT ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2025-07-10 | — | — | US | disclosed |
| EP-4370157-A1 | ASGPR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES | Lycia Therapeutics, Inc. (US) | 2024-05-22 | — | — | EP | disclosed |
| EP-4334360-A2 | POTENT ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS | Avilar Therapeutics, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| US-11840691-B2 | Compound and application thereof | KYLONOVA (XIAMEN) BIOPHARMA CO., LTD. (CN) | 2023-12-12 | — | — | US | disclosed |
| US-11840691-B2 | Compound and application thereof | KYLONOVA (XIAMEN) BIOPHARMA CO., LTD. (CN) | 2023-12-12 | — | — | US | disclosed |
| US-20230374513-A1 | NOVEL COMPOUND AND APPLICATION THEREOF | KYLONOVA (XIAMEN) BIOPHARMA CO., LTD. (CN) | 2023-11-23 | — | — | US | disclosed |
| US-20230374513-A1 | NOVEL COMPOUND AND APPLICATION THEREOF | KYLONOVA (XIAMEN) BIOPHARMA CO., LTD. (CN) | 2023-11-23 | — | — | US | disclosed |
| US-20230357776-A1 | COMPOSITIONS AND METHODS FOR MODULATING COMPLEMENT FACTOR B EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2023-11-09 | — | — | US | disclosed |
| US-20230357776-A1 | COMPOSITIONS AND METHODS FOR MODULATING COMPLEMENT FACTOR B EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2023-11-09 | — | — | US | disclosed |
| US-11732265-B2 | Compositions and methods for modulating complement factor B expression | IONIS PHARMACEUTICALS, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-20150126718-A1 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | ISIS PHARMACEUTICALS, INC. (US) | 2015-05-07 | — | — | US | disclosed |
| US-20150126718-A1 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | ISIS PHARMACEUTICALS, INC. (US) | 2015-05-07 | — | — | US | disclosed |
| WO-2015042447-A1 | TARGETED THERAPEUTIC NUCLEOSIDES AND THEIR USE | ISIS PHARMACEUTICALS, INC. (US) | 2015-03-26 | — | — | WO | disclosed |
| US-20140343123-A1 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | ISIS PHARMACEUTICALS, INC. (US) | 2014-11-20 | — | — | US | disclosed |
| US-20140343123-A1 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | ISIS PHARMACEUTICALS, INC. (US) | 2014-11-20 | — | — | US | disclosed |
| WO-2014179626-A2 | COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN C-III EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2014-11-06 | — | — | WO | disclosed |
| WO-2014179627-A2 | COMPOSITIONS AND METHODS FOR MODULATING HBV AND TTR EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2014-11-06 | — | — | WO | disclosed |
| WO-2014179620-A1 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | ISIS PHARMACEUTICALS, INC. (US) | 2014-11-06 | — | — | WO | disclosed |
| WO-2014179629-A2 | COMPOSITIONS AND METHODS | ISIS PHARMACEUTICALS, INC. (US) | 2014-11-06 | — | — | WO | disclosed |
| WO-2014179625-A1 | COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN (a) EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2014-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230374513-A1 | NOVEL COMPOUND AND APPLICATION THEREOF | GALNT6, GALNT3, GALNT14 | CTRB1 2167/4885HTT 4264/4885LMNA 606/4885 |
| US-20250223280-A1 | POTENT ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS | ASGR1, FCGR2A, FCGR3B | CTRB1 1680/4885HTT 4253/4885LMNA 3492/4885 |
| US-11840691-B2 | Compound and application thereof | GALNT6, GALNT3, GALNT14 | CTRB1 2040/4885HTT 4090/4885LMNA 489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.